Branch Retinal Vein Occlusion (BRVO)

01Pathophysiology

Branch retinal vein occlusion occurs at arteriovenous crossing points, where a retinal arteriole and venule share a common adventitial sheath. In patients with chronic hypertension or atherosclerosis, the arteriole wall becomes thickened and rigid. This thickened arteriole mechanically compresses the underlying venule against the shared connective tissue sheath. The compression creates turbulent blood flow within the vein, damages the venous endothelium, and activates the coagulation cascade, ultimately forming a thrombus at the AV crossing.

Once the vein is occluded, venous outflow from the upstream retinal territory is blocked. Hydrostatic pressure rises in the capillary bed drained by that vein, causing plasma and red blood cells to leak into the surrounding retinal tissue. This is why the hallmark finding is flame-shaped hemorrhages confined to one sector of the retina rather than all four quadrants (which would indicate central retinal vein occlusion instead).

The increased intravascular pressure also disrupts the inner blood-retinal barrier, leading to macular edema, which is the most common cause of vision loss in BRVO. In more severe (ischemic) cases, widespread capillary closure triggers retinal hypoxia. The ischemic retina responds by upregulating vascular endothelial growth factor (VEGF), which promotes pathological neovascularization. These new, fragile vessels can bleed into the vitreous cavity (vitreous hemorrhage) or grow over the iris (rubeosis iridis), potentially causing neovascular glaucoma.

The superotemporal quadrant is the most frequently affected location because it has the highest density of AV crossings.

02Classification and Clinical Manifestation

Key clinical features by phase

03Diagnostic Workup

The best initial test is a thorough dilated fundoscopic examination. In a clinical vignette, the classic description of flame-shaped hemorrhages limited to one retinal quadrant with dilated veins should immediately point you toward BRVO. No additional testing is needed to make the clinical diagnosis at the bedside.

OCT is then obtained to evaluate the macula. This is the test that drives treatment decisions because persistent macular edema (central subfield thickness typically >300 micrometers) is the primary indication for intravitreal therapy. Without OCT documentation of edema, you do not treat.

Fluorescein angiography serves as the gold standard for classifying the severity of occlusion. The critical determination is whether the BRVO is ischemic or non-ischemic, because ischemic BRVO carries a substantially higher risk of neovascularization. FA identifies areas of capillary non-perfusion: when 5 or more disc areas of capillary dropout are present, the BRVO is classified as ischemic. FA also detects early neovascularization that may not be visible on fundoscopy alone.

A systemic workup is essential because BRVO is frequently the first clinical manifestation of undiagnosed hypertension, diabetes, or hyperlipidemia. In young patients (<50 years) without traditional cardiovascular risk factors, a hypercoagulability panel should be ordered to evaluate for thrombophilic conditions.

04Management and Treatment

Acute stabilization begins with confirming the diagnosis through fundoscopy and obtaining OCT. If the patient presents with good visual acuity (20/40 or better) and no clinically significant macular edema, observation with serial monitoring every 4 to 6 weeks is appropriate. Systemic risk factor control is paramount: blood pressure optimization, glycemic control, and lipid management.

For patients with vision-reducing macular edema, the first-line treatment is intravitreal anti-VEGF injection. The landmark BRAVO trial established ranibizumab 0.5 mg as effective therapy, and the VIBRANT trial demonstrated aflibercept 2 mg superiority over grid laser. Treatment is initiated with monthly injections for 6 months, followed by a treat-and-extend protocol where the interval between injections is gradually lengthened as long as the macula remains dry on OCT. Most patients require treatment for 2 to 3 years, though some achieve sustained resolution.

Intravitreal dexamethasone implant (Ozurdex, 0.7 mg) is an alternative for patients who are pseudophakic (prior cataract surgery), who respond poorly to anti-VEGF, or who cannot comply with monthly injections. The GENEVA trial supported its use. However, corticosteroid-related complications must be monitored: intraocular pressure (IOP) elevation occurs in approximately 15-20% of patients, and cataract progression is expected in phakic eyes. Because of these side effects, anti-VEGF remains the preferred first-line agent in phakic patients.

Grid/sector laser photocoagulation was historically the standard treatment for macular edema based on the Branch Vein Occlusion Study (BVOS). The BVOS recommended grid laser for eyes with macular edema and visual acuity of 20/40 or worse that persisted for at least 3 months. While still a valid treatment, grid laser has been largely supplanted by anti-VEGF in current practice. Laser remains the primary treatment for retinal neovascularization: scatter (sector) photocoagulation is applied to the ischemic retinal territory when neovascularization is detected.

Contraindications and cautions: In pregnant patients, anti-VEGF agents are generally avoided due to potential teratogenic effects from systemic VEGF inhibition; observation or laser is preferred. In patients with recent thromboembolic events (stroke, myocardial infarction within 3 months), the theoretical systemic risk of anti-VEGF should be weighed against benefits, though intravitreal doses result in minimal systemic absorption.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap with BRVO questions is confusing it with CRVO. Both conditions share the same risk factors and present with sudden painless vision loss, retinal hemorrhages, and dilated veins. The discriminating feature is the distribution of hemorrhages: BRVO is sectoral (one quadrant), while CRVO involves all four quadrants. If a vignette describes hemorrhages "in the superotemporal quadrant" or "along the distribution of a single vein," that is BRVO. If the vignette describes a "diffuse" or "four-quadrant" hemorrhagic picture, that is CRVO.

A second frequent error involves treatment sequencing. Students sometimes select grid laser photocoagulation as the first-line treatment for macular edema because it appears in older references. Current guidelines and landmark trials (BRAVO, VIBRANT) have established intravitreal anti-VEGF as the standard first-line therapy for vision-reducing macular edema. Grid laser is now considered a second-line or adjunctive option. However, for neovascularization, laser photocoagulation remains the primary intervention, not anti-VEGF alone.

A third pitfall is forgetting the systemic workup. BRVO is not merely an eye disease. It is a marker of underlying cardiovascular disease. A vignette may present a patient with new-onset BRVO and ask for the "most important next step" beyond ophthalmic treatment. The answer is blood pressure measurement and cardiovascular risk factor screening (fasting glucose, lipid panel). In a younger patient without conventional risk factors, the tested concept shifts to ordering a hypercoagulability panel.

Finally, be alert to the complication timeline. The most common cause of vision loss in BRVO is macular edema (not neovascularization). Neovascularization is a later complication that occurs primarily in ischemic BRVO, typically developing within the first 6 to 12 months. A question asking about the "most likely cause of persistent decreased vision at 3 months" in a BRVO patient is testing your knowledge that the answer is macular edema, not hemorrhage obscuring the macula (hemorrhages often clear) and not neovascularization (too early and only in ischemic subtype).

The core competency being tested is your ability to recognize the sectoral hemorrhage pattern, correctly classify the vascular event, initiate appropriate imaging (OCT for treatment decisions, FA for ischemic classification), choose anti-VEGF as first-line for macular edema, and connect the ocular finding to underlying systemic disease.